Dataset Information

Harish2009 - nuclear–cytoplasmic ERK oscillation model

ABSTRACT: This model is based on the supplementary material of the publication “Rapid and sustained nuclear–cytoplasmic ERK oscillations induced by epidermal growth factor This model is an Antimony version of the original MATLAB model.

SUBMITTER: Yirui Chen

PROVIDER: MODEL2306170002 | BioModels | 2023-06-19

REPOSITORIES: BioModels

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MODEL2306170002?filename=Model%20of%20nuclear_cytoplasmic%20ERK%20oscillations%20induced%20by%20epidermal%20growth%20factor.py	Other
	MODEL2306170002?filename=Model%20of%20nuclear_cytoplasmic%20ERK%20oscillations%20induced%20by%20epidermal%20growth%20factor.xml	Xml

Items per page:

1 - 2 of 2

Publications

Rapid and sustained nuclear-cytoplasmic ERK oscillations induced by epidermal growth factor.

Shankaran Harish H Ippolito Danielle L DL Chrisler William B WB Resat Haluk H Bollinger Nikki N Opresko Lee K LK Wiley H Steven HS

Molecular systems biology 20091201

Although the ERK pathway has a central role in the response of cells to growth factors, its regulatory structure and dynamics are incompletely understood. To investigate ERK activation in real time, we expressed an ERK-GFP fusion protein in human mammary epithelial cells. On EGF stimulation, we observed sustained oscillations of the ERK-GFP fusion protein between the nucleus and cytoplasm with a periodicity of approximately 15 min. The oscillations were persistent (>45 cycles), independent of ce ...[more]

PMID: 19953086

Similar Datasets

Project description:About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We had previously demonstrated that dimerization is essential for ERK extranuclear but not nuclear signaling. Furthermore, by molecular biology approaches, we showed that specifically inhibiting ERK extranuclear component, by impeding ERK dimerization, is sufficient for curtailing tumor progression. Here, we have identified a small molecule inhibitor for ERK dimerization in vitro and in vivo that, without affecting ERK phosphorylation, prevents tumorigenesis driven by Ras-ERK pathway oncogenes, both in cellular and animal models. Importantly, this compound is unaffected by resistance-acquisition processes that hamper “classical” Ras-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two novel concepts in cancer therapy: 1) The blockade of sublocalization-specific sub-signals, rather than total signals, as a means of effectively counteracting oncogenic Ras-ERK signaling. 2) Targeting regulatory protein-protein interactions such as dimerization, rather than catalytic activities, within a signaling route, as an approach for producing effective anti-tumoral agents. Strategies aimed at preventing aberrant flux through this route remain an attractive option for therapeutic intervention in cancer. In this respect, drugs inhibiting the kinase activities of BRaf and MEK have yielded promising results. A375p cells treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours. mRNA from A375p cells was extrated using RNeasy mini kit (Qiagen, Germany) according to the manufacturer's instructions. Cells were previously treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours.